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Treatment of Facial Nerve Palsy 
Based on Genetic Analysis of the 
Facial Muscles
Hiroshi Moriyama
Abstract
Details of the molecular biological features of facial nerve palsy have not been 
widely reported in textbooks. I performed a genetic analysis of facial muscle specimens 
from Japanese patients with moderate (House-Brackmann facial nerve grading system 
III) and severe (House-Brackmann facial nerve grading system V) dysfunctions due to 
Bell’s palsy and rats, after facial nerve resection (total paralysis). Microarray analysis 
of gene expression was performed using specimens from both the healthy and affected 
sides, and gene expressions were compared. Changes in gene expression were defined 
as a palsy/healthy side ratio >2.0 or <0.5. I observed changes of gene expression; in 
particular, genes for muscle, neuron, and energy function showed changes with the 
severity of facial nerve palsy. This study may aid the development of new treatments 
and diagnostic/prognostic markers based on the severity of palsy.
Keywords: facial nerve palsy, facial muscle, orbicularis oculi, microarray analysis, 
gene expression
1. Introduction
Bell’s palsy is an acute, idiopathic, unilateral facial nerve paresis or paralysis 
of unknown cause. It leads to the partial or complete inability to voluntarily move 
facial muscles on the affected side of the face and may be occurring with equal 
frequency on the right and left sides of the face. Although typically self-limited, 
symptoms of Bell’s palsy may include oropharyngeal or facial numbness, disturbed 
taste on the anterior part of the tongue, impaired tolerance to ordinary levels of 
noise, mild pain in or behind the ear, significant oral incompetence, and an inability 
to close the eyelid, leading to potential eye injury. Clinically important improve-
ment without intervention occurs within 3 weeks after onset of symptoms in 85% 
of patients and within 3–5 months in the remaining 15% [1]. Patients failing to show 
signs of improvement by 3 weeks may have suffered Wallerian degeneration of the 
facial nerve, leading to residual paresis and abnormal branching of regenerating 
axons, or may have an alternative diagnosis that requires identification by specialist 
examination or investigations. Among patients with Bell’s palsy, 71% obtained their 
normal facial muscle function [1]. Sequelae were slight in 12% of patients with Bell’s 
palsy, mild in 13%, and severe in 4% [1]. Incomplete recovery of facial expression 
may have a long-term impact on quality of life. Some patients with Bell’s palsy never 
recover despite treatment by pharmacotherapy and facial nerve decompression 
surgery. Physicians take the bold course of operation as a last resort. Contemporary 
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reconstructive options include neurotization procedures (a new motor nerve is 
used to restore innervation to a viable muscle), contiguous regional muscle transfer 
(most commonly temporalis muscle transfer), and microsurgical free muscle trans-
fer [2]. Additionally, some patients do not wish to undergo plastic and reconstruc-
tive surgery, and at present, there is no effective treatment for them [3]. Research 
on myogenin expression in the facial muscles following resection or compression of 
the facial nerve [4] indicated that facial muscle gene analysis might be a promising 
way to predict the outcome of facial palsy even at an early stage of the disease [4]. I 
thus performed a genetic analysis of the facial muscles in patients with Bell’s palsy 
and in rats after facial nerve resection and assessed its molecular biological aspects 
as a pathway to new treatments.
2. Materials and methods
2.1 Human specimens
The materials used to study the microarray analysis were obtained from the 
orbicularis oculi muscles of six Japanese patients with Bell’s palsy (females in their 
60s). Three patients were judged to be House-Brackmann facial nerve grading 
system III (moderate dysfunction), and the other three were judged to be House-
Brackmann facial nerve grading system V (severe dysfunction). Both groups had 
previously received nonsurgical conservative treatment using steroids and so on but 
had not undergone facial nerve decompression surgery. All the patients were treated 
with plastic and reconstructive procedures at 1.5 years after the onset of facial 
paralysis. Both groups underwent blepharoplasty of the superior eyelid for blepha-
roptosis on the affected side. They also underwent blepharoplasty on the healthy 
side for esthetic reasons. Biopsy materials were obtained from the palpebral part of 
orbicularis oculi on both the healthy side and the side with palsy. The microarray 
analysis of gene expression was performed using Affymetrix Human Gene 1.0 ST 
arrays (Affymetrix Inc., Santa Clara, CA, USA), and gene expressions were com-
pared between the two sides. Changes of gene expression were defined as a palsy/
healthy side expression ratio >2.0 or <0.5.
This study was approved by the local ethics review board (No. 149) at the Showa 
University Hospital. I conducted and had supervisory control of this study accord-
ing to the Ethical Principles for Medical Research Involving Human Subjects in the 
Declaration of Helsinki. I provided all patients with detailed information about this 
study and obtained written informed consent prior to inclusion from both patients 
and doctors for participation in this study.
2.2 Rat specimens
Three male Slc: Wistar/ST rats weighing 300 g (12 weeks old) were used. 
The management of environmental variables of rats was as follows: (1) the room 
temperature range for rat housing between 21 and 23°C, (2) the humidity at the 
level of rat cages of 40–70%, (3) the room ventilation rates of about 15–20 air 
changes per hour, and (4) the light cycles of 12/12 hours light/dark. The animals 
were allowed to have food and water provided ad libitum until the end of the 
experiment.
Each animal was anesthetized with an intraperitoneal injection of 0.15 mg/
kg of medetomidine hydrochloride, 2.0 mg/kg of midazolam, and 2.5 mg/kg 
of butorphanol tartrate and fixed on an experimental table in the prone posi-
tion. The face was shaved and cleaned, and a skin incision was made to expose 
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the extratemporal portion of the facial nerve bilaterally. On the nerve resection 
side (right side), the main trunk of the facial nerve was cut just distal to the 
stylomastoid foramen, forming a 7 mm gap in the trunk to avoid regeneration. In 
sham surgery group, the facial nerve on the opposite side (left side) was exposed 
without further manipulation. The rats were returned to the animal room after 
completion of these procedures.
The rats were sacrificed under deep anesthesia by intraperitoneal administra-
tion of pentobarbital (150 mg/kg) on the third postoperative week. A piece of 
orbicularis oculi muscle was obtained from each side and immediately immersed in 
RNAlater solution (QIAGEN N. V.; Venlo, Netherlands), for gene expression analy-
sis. The microarray analysis of gene expression was performed using Affymetrix 
Human Gene 1.0 ST arrays (Affymetrix Inc., Santa Clara, CA, USA), and gene 
expression was compared between the two sides. Changes of gene expression were 
defined as a palsy/healthy side expression ratio >2.0 or <0.5.
Under the approval of the Ethics Committee of Nagoya City University Graduate 
School of Medical Sciences (No. H27M-74), the present study was conducted fol-
lowing the Guidelines for Animal Experimentation at the above institute. All efforts 
were made to minimize suffering and the number of animals used, as described in 
the experimental protocol.
3. Results
Table 1 summarizes the data from the three severities of facial nerve palsy 
(House-Brackmann facial nerve grading system III, V, and VI). Only 13 genes 
showed similar changes between patients with moderate dysfunction and those 
with severe dysfunction, and only one gene showed similar changes between 
patients with moderate dysfunction and rats with total paralysis. In contrast, 
333 genes showed similar changes between patients with severe dysfunction and 
rats with total paralysis. The overall changes indicated that patients with moder-
ate dysfunction differed from those with severe dysfunction and rats with total 
paralysis.
Table 1. 
Comparison of changes in gene expression between the three severities of facial nerve palsy. Changes of 
gene expression were defined as a palsy/healthy side ratio > 2.0 or < 0.5.  indicates that most genes in 
the category were downregulated.  indicates that some genes in the category were downregulated.  
indicates that most genes in the category were upregulated.  indicates that some genes in the category were 
upregulated.  indicates that expression of genes in the category did not change. Numbers (mean values) on 
the right side of the arrows indicate the number of genes showing changes.
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3.1 Patients with moderate dysfunction
A total of 174 genes showed changes, which was a relatively low number. Genes 
in the neuron category tended to show downregulation, while most genes show-
ing changes in the muscle category were upregulated. Genes related to muscle 
components and genes involved in muscle movement were also upregulated. Only 
two energy production genes were upregulated, and both were important genes 
related to the glycolysis pathway. I did not find any large functional clusters except 
for these functional categories. Some genes involved in cell proliferation and cell 
division showed downregulation. However, genes linked to stress markers and 
apoptosis did not show upregulation (Table 1).
3.2 Patients with severe dysfunction
A total of 763 genes showed changes of expression. Among 59 genes with 
changes in the neuron category, 39 genes showed upregulation and 20 genes showed 
downregulation. Most genes showing changes in the muscle and energy categories 
showed downregulation, but some genes related to immunity, inflammation, and 
stress, in contrast, showed upregulation (Table 1).
3.3 Rats with total paralysis
A total of 1102 genes showed changes of expression. Among 47 genes with 
changes in the neuron category, 29 genes were upregulated and 18 were downregu-
lated. Some genes linked to immunity, stress, and autophagy were also upregulated. 
Moreover, most genes showing changes in the inflammation category were upregu-
lated. In contrast, most genes showing changes in the muscle and energy categories 
showed downregulation (Table 1).
4. Discussion
The total number of genes showing changes of expression (mean values for the 
patients) in the patients with moderate dysfunction was 174, compared to 763 in the 
patients with severe dysfunction. The total number of genes that changed in both 
groups was 25, but only 13 genes showed changes of expression in the same direction. 
Next, the total number of genes showing changes of expression (mean values for the 
patients and rats) in the patients with moderate dysfunction was 174 but 1102 in the 
rats with total paralysis. The total number of genes that changed in both groups was 
19, but only one gene showed changes of expression in the same direction. These find-
ings indicated that the condition of moderate dysfunction differed greatly from that 
of severe dysfunction in patients with facial nerve palsy and rats with total paralysis.
Considering these findings, I speculate that, if facial nerve conduction is 
reduced in moderate dysfunction, the orbicularis oculi muscle cannot function 
well and the patient presents with paresis. To improve this situation, regeneration 
of muscle tissue is promoted. Researchers reported that innervation is required for 
normal energy production in muscles [5]. Therefore, due to denervation, there was 
the decrease in energy production in muscles with paresis, but patients with moder-
ate dysfunction had some energy production related to regeneration of muscle tis-
sue. There was very little energy production or regeneration of the affected muscles 
because of the largely abolished facial nerve conduction in patients with severe 
dysfunction. Accordingly, the muscles innervated by the facial nerve did not show 
much regeneration, but the neurons themselves showed accelerated regeneration.
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On the basis of these genetic findings, I suggest that neurorrhaphy and nerve 
grafting of the facial nerve are appropriate for patients with moderate dysfunction. 
These procedures will improve facial nerve conduction, leading to the increase 
in energy production for the regeneration of muscle tissue. However, there was 
little muscle regeneration and very low energy production in patients with severe 
dysfunction, although they showed acceleration of neuronal regeneration. These 
findings may explain why neurorrhaphy and nerve grafting of the facial nerve 
are unsuccessful if performed more than 1 year after the onset of facial palsy. 
Many authors have reported that recovery is better if the interval between injury 
to the facial nerve and repair surgery on the facial nerve is shorter [6–8]. Because 
improvement of facial nerve conduction is incomplete in patients with severe dys-
function, I consider that promoting the regeneration of muscle tissue and energy 
production is necessary. It is possible that some form of regenerative medicine, such 
as the use of induced pluripotent stem (iPS) cells, could be employed to improve 
muscle regeneration [9]. However, before such treatments become available for 
clinical use, I propose administration of pyruvate or mitochonic acid 5 (MA-5) as 
a practical way to promote muscle regeneration and energy production. Pyruvate 
plays a pivotal role in central carbon metabolism. Pyruvate is generated from sev-
eral sources, including the end product of glycolysis, the oxidation of lactate, or as 
the transamination of alanine. Pyruvate is crucial for ATP generation in mitochon-
dria and for driving several major biosynthetic pathways intersecting the citric acid 
cycle. In addition, it is well known that pyruvate can eliminate hydrogen peroxide 
by a nonenzymatic reaction to form acetate, carbon dioxide, and water [10]. This 
antioxidant activity of pyruvate may be also beneficial for patients with mitochon-
drial disorders, because the respiratory defects increase the leakage of reactive 
oxygen species from the mitochondria. Thus, administration of pyruvate restores 
the production of adenosine 5′-triposphate (ATP) via the glycolytic pathway. MA-5 
targets the mitochondrial protein mitofilin at the crista junction of the inner mem-
brane and could be a novel treatment for diseases associated with mitochondrial 
dysfunction [11, 12]. In Bell’s palsy patients with severe dysfunction, it seems that 
mitochondrial cytopathy develops with impairment of ATP synthesis. As this state 
is similar to that in various mitochondrial diseases, I consider that pyruvate therapy 
[13, 14] and the administration of MA-5 could be effective. I also propose neurovas-
cular free muscle transfer as effective surgery for patients with severe dysfunction 
of facial palsy. Neurovascular free muscle transfer is one of the main reconstructive 
surgeries for established or long-standing facial palsy [15], but it also seems to be 
suitable for severe facial palsy based on genetic findings in this study, and I suggest 
that neurovascular free muscle transfer could be more effective than facial nerve 
neurorrhaphy with nerve grafting in patients with severe dysfunction.
Grading of facial function is necessary for evaluating and communicating the 
spontaneous course and the results of medical and surgical treatment of facial 
palsy [16, 17]. Several grading systems for the assessment of facial nerve function 
using gross (e.g., the House-Brackmann grading system) [16] or regional (e.g., the 
Yanagihara grading system) [18] scales have been proposed. In this study, patients 
with severe dysfunction who were judged as grade V by the House-Brackmann 
system also scored 8–14 points with the Yanagihara system. The clinical descrip-
tion in patients with severe dysfunction is barely perceptible motion, whereas 
that in patients with total paralysis (House-Brackmann grading system VI) is 
no movement. As these two clinical descriptions differ widely, I compared the 
changes in gene expression between patients with severe dysfunction and rats 
with total paralysis (Table 1). The total number of genes that changed in both 
groups was 403 and that of gene expression in the same direction accounted for 
around 83% (333 genes). Some genes linked to immunity, inflammation (most 
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genes showing changes in rats), and stress were upregulated in both groups. In the 
neuron category, the number of upregulated genes tended to be higher than the 
number of downregulated genes in both groups. Moreover, in both groups, most 
genes showing changes in the energy and muscle categories were downregulated. 
As mentioned above, the condition of moderate dysfunction differed widely from 
that of severe dysfunction in patients with facial nerve palsy and rats with total 
paralysis, but the overall changes indicated that gene expressions in patients with 
severe dysfunction were similar to those in rats with total paralysis. In general, 
the molecular biological changes after neurotmesis are as follows: (1) nerve 
transection produces morphological changes in the neuronal perikarya known as 
chromatolysis or axon reaction, and the changes include swelling of the cell body, 
nucleolar enlargement, displacement of the nucleus to the periphery, and dissolu-
tion of Nissl bodies [19] and (2) axotomized neurons respond by upregulation of 
regeneration-associated genes in association with conversion of the neuron from a 
transmitting to a growth state [20]. Remarkable molecular biological changes after 
neurotmesis, as described above, lasted for 10–20 days. Rat specimens in this study 
were obtained on the third postoperative week. Therefore, the rat models in this 
study closely resembled patients with total paralysis (House-Brackmann grading 
system VI). Synthesizing these results based on molecular biological analyses, I 
suggest that clinicians treat patients with severe dysfunction (House-Brackmann 
grading system V) with the same treatment as for patients with total paralysis 
(House-Brackmann grading system VI).
5. Conclusions
I conclude that the gene expression in facial nerve palsy changes with the degree 
of facial nerve palsy. This study will aid in the development of new treatments and 
diagnostic/prognostic markers based on the severity of facial nerve palsy.
Acknowledgements
I thank Prof. Nobuyuki Mitsukawa for providing human specimens and Prof. 
Shingo Murakami and Dr. Akira Inagaki for providing animal specimens. I thank 
Dr. Yoshiyuki Takahara for helping in analyzing the DNA microarray and Ms. Ikuko 
Moriyama for assistance in preparing the manuscript.
Conflicts of interest
The author has no conflicts of interest to declare.
Ethics approval of research
The local Ethics Review Board of Showa University Hospital approved 
the study protocol (No. 149) according to the principles of the Declaration of 
Helsinki. All the patients were provided with detailed information about the 
study and provided written informed consent prior to their inclusion. I abided 
by the Ethical Principles for Medical Research Involving Human Subjects out-
lined in the Declaration of Helsinki. With regard to animal experimentation, the 
7© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Treatment of Facial Nerve Palsy Based on Genetic Analysis of the Facial Muscles
DOI: http://dx.doi.org/10.5772/intechopen.81933
present study was conducted following the Guidelines for Institutional Animal 
Experimentation under the approval of the Ethics Committee of Nagoya City 
University Graduate School of Medical Sciences (No. H27M-74). I made every 
effort to minimize pain, discomfort for the animals and the number of animals 
used, as written in the experimental protocol.
Financial support and disclosure
This work was supported by the annual budget of Showa University for scientific 
research. I certify that the funding agencies had no involvement in the design, data 
collection, analysis, or interpretation of the results. The corresponding author had 
full access to all the data in the study and had final responsibility for the decision to 
submit for publication.
Author details
Hiroshi Moriyama
Department of Anatomy, Showa University School of Medicine, Shinagawa-ku, 
Tokyo, Japan
*Address all correspondence to: veloce@med.showa-u.ac.jp
8Selected Topics in Facial Nerve Disorders
[1] Peitersen E. Bell’s palsy: The 
spontaneous course of 2,500 peripheral 
facial nerve palsies of different 
etiologies. Acta Oto-Laryngologica. 
Supplementum. 2002;549:4-30
[2] Garcia R, Hadlock T, Klebuc M, 
Simpson R, Zenn M, Marcus J.  
Contemporary solutions for the 
treatment of facial nerve paralysis. 
Plastic and Reconstructive Surgery. 
2015;135:1025e-1046e
[3] Holland J, Bernstein J. Bell’s palsy. 
BMJ Clinical Evidence. 2011;2011:1204
[4] Teraoka M, Hato N, Takahashi H, 
Komobuchi H, Sawai N, Okada M, 
et al. Myogenin expression in facial 
muscle following damage to the facial 
nerve. Acta Oto-Laryngologica. 
2012;132:783-787
[5] Sato D, Shinzawa G, Kusunoki M,  
Matsui T, Sasaki H, Feng Z, et al. 
Effects of electrical microstimulation of 
peripheral sympathetic nervous fascicle 
on glucose uptake in rats. Journal of 
Artificial Organs. 2013;16:352-358
[6] Conley J, Baker DC. Hypoglossal-
facial nerve anastomosis for 
reinnervation of the paralyzed face. 
Plastic and Reconstructive Surgery. 
1979;63:63-72
[7] Gavron JP, Clemis JD. Hypoglossal-
facial nerve anastomosis: A review 
of forty cases caused by facial nerve 
injuries in the posterior fossa. The 
Laryngoscope. 1984;94:1447-1450
[8] Kunihiro T, Kanzaki J, Yoshihara S, 
Satoh Y, Satoh A. Hypoglossal-facial 
nerve anastomosis after acoustic 
neuroma resection: lnfluence of the 
time of anastomosis on recovery of 
facial movement. ORL: Journal for 
Otorhinolaryngology and Its Related 
Specialties. 1996;58:32-35
[9] Masumoto H, Ikuno T, Takeda M, 
Fukushima H, Marui A, Katayama S, 
et al. Human iPS cell-engineered cardiac 
tissue sheets with cardiomyocytes and 
vascular cells for cardiac regeneration. 
Scientific Reports. 2014;4:6716. DOI: 
10.1038/srep06716
[10] Nath K, Ngo E, Hebbel R, Croatt A,  
Zhou B, Nutter L. alph-Ketoacids 
scavenge H2O2 in vitro and in vivo and 
reduce menadione-induced DNA injury 
and cytotoxicity. The American Journal 
of Physiology. 1995;268:C227-C236
[11] Suzuki T, Yamaguchi H, Kikusato M, 
Hashizume O, Nagatoishi S, Matsuo 
A, et al. Mitochonic acid 5 binds 
mitochondria and ameliorates renal 
tubular and cardiac myocyte damage. 
Journal of the American Society of 
Nephrology. 2016;27:1925-1932
[12] Suzuki T, Yamaguchi H, Kikusato M, 
Matsuhashi T, Matsuo A, Sato T, 
et al. Mitochonic acid 5 (MA-5), 
a derivative of the plant hormone 
indole-3-acetic acid, improves survival 
of fibroblasts from patients with 
mitochondrial diseases. The Tohoku 
Journal of Experimental Medicine. 
2015;236:225-232
[13] Tanaka M, Nishigaki Y, Fuku N, 
Ibi T, Sahashi K, Koga Y. Therapeutic 
potential of pyruvate therapy for 
mitochondrial diseases. Mitochondrion. 
2007;7:399-401
[14] Kerr DS. Review of clinical trials 
for mitochondrial disorders: 1997-2012. 
Neurotherapeutics. 2013;10:307-319
[15] Takushima A, Harii K, Asato H, 
Kurita M, Shiraishi T. Fifteen-year 
survey of one-stage latissimus dorsi 
muscle transfer for treatment of 
longstanding facial paralysis. Journal 
of Plastic, Reconstructive & Aesthetic 
Surgery. 2013;66:29-36
References
9Treatment of Facial Nerve Palsy Based on Genetic Analysis of the Facial Muscles
DOI: http://dx.doi.org/10.5772/intechopen.81933
[16] House JW, Brackmann DE. Facial 
nerve grading system. Otolaryngology 
and Head and Neck Surgery. 
1985;93:146-147
[17] House JW. Facial nerve grading 
systems. The Laryngoscope. 
1983;93:1056-1069
[18] Yanagihara N. Grading of facial 
palsy. In: Fisch U, editor. Proceedings 
of the Third International Symposium 
on Facial Nerve Surgery. Zurich: Kugler 
Medical Publications; 1976. pp. 533-535
[19] Kreutzberg GW. Microglia, 
the first line of defense in brain 
pathologies. Arzneimittel-Forschung. 
1995;45:357-360
[20] Boyd JG, Gordon T. Neurotrophic 
factors and their receptors in axonal 
regeneration and functional recovery 
after peripheral nerve injury. Molecular 
Neurobiology. 2003;27:277-324
